SCHEMBL24924592

SCHEMBL24924592

O=C1C=C(c2ccncc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
NOTUM Q6P988 1/20 0.37
MAPK14 Q16539 2/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
CDC7 O00311 3/20 0.35
PKN1 Q16512 2/20 0.35
PKN2 Q16513 2/20 0.35
MAPK1 P28482 2/20 0.35
CDK9 P50750 2/20 0.35
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35
PLK4 O00444 1/20 0.35
MAPK13 O15264 1/20 0.35
DAPK3 O43293 1/20 0.35
DYRK3 O43781 1/20 0.35
ROCK2 O75116 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11279823 0.87 MAPK14 (0.41) CYP11B1CYP11B2MAPTLMNANOTUM
SCHEMBL16321456 0.78 CYP11B2 (0.58) CYP11B1CYP11B2MAPTLMNAHTT
SCHEMBL11622434 0.77 CYP11B1 (0.39) CYP11B1CYP11B2MAPTMAPK14PKN1
SCHEMBL731336 0.76 NPC1 (0.50) MAPTLMNANPC1HTTRAB9A
SCHEMBL5228519 0.73 HTR2C (0.39) MAPTMAPK1GAANPC1RAB9A
Ethylene SCHEMBL3236411 0.71 MAPT (0.37) CYP11B1CYP11B2MAPTLMNANOTUM
SCHEMBL7488496 0.68 IDO1 (0.38) MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL8649025 0.68 PTGS2 (0.42) MAPTMAPK1GAANPC1RAB9A
SCHEMBL2165399 0.68 MAPT (0.39) CYP11B1CYP11B2MAPTLMNANOTUM
SCHEMBL24923799 0.68 ALDH1A1 (0.44) MAPTNOTUMMAPK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2024-07-09 US disclosed
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2024-07-09 US disclosed
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2023-01-24 US disclosed
CN-113195055-A 5-membered heteroaryl carboxamide compounds for HBV therapy 组装生物科学股份有限公司 2021-07-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV HCCS, HAVCR2, MAVS CYP11B1 1644/4885CYP11B2 1999/4885MAPT 3215/4885
US-12030869-B2 5-membered heteroaryl carboxamide compounds for treatment of HBV HCCS, HAVCR2, MAVS CYP11B1 1644/4885CYP11B2 1999/4885MAPT 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.